Search Results

Dynavax Technologies announced Tuesday that the FDA issued a Complete Response Letter to the company’s sBLA to include a four-dose regimen of Heplisav-B vaccine for adult hemodialysis patients.

Dynavax Technologies Corporation, a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, announced that the Company will present at the following upcoming investor conferences during the month of June.

Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company’s investigational vaccine candidate being developed for the prevention of shingles (herpes zoster), a debilitating disease caused by the varicella-zoster virus.

Dynavax Technologies Corporation, a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, reported financial results and provided a business update for the quarter ended March 31, 2024.

Dynavax Technologies Corporation provided a regulatory update for the Company’s supplemental Biologics License Application to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine, Adjuvanted] regimen for adults on hemodialysis.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close.

Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the Company will present at TD Cowen’s 44th Annual Health Care Conference on Monday, March 4 at 10:30 a.m. ET.